Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant (dimdazenil) vs eszopiclone for insomnia in recurrent depression
ChiCTR2500110369Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dimdazenil in recurrent depressive disorder (RDD) and Insomnia (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Insomnia Severity Index (ISI) at week 4. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
dimdazenil
03
Conditions
recurrent depressive disorder (RDD)Insomnia
Beyond the preview
Go deeper on ChiCTR2500110369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110369.